GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Shiller PE Ratio

Bioasis Technologies (FRA:107) Shiller PE Ratio : (As of Sep. 21, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioasis Technologies Shiller PE Ratio Historical Data

The historical data trend for Bioasis Technologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Shiller PE Ratio Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioasis Technologies's Shiller PE Ratio

For the Biotechnology subindustry, Bioasis Technologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Shiller PE Ratio falls into.



Bioasis Technologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bioasis Technologies's E10 for the quarter that ended in Nov. 2022 is calculated as:

For example, Bioasis Technologies's adjusted earnings per share data for the three months ended in Nov. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Nov. 2022 (Change)*Current CPI (Nov. 2022)
=-0.007/125.6074*125.6074
=-0.007

Current CPI (Nov. 2022) = 125.6074.

Bioasis Technologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201302 -0.022 97.953 -0.028
201305 -0.015 98.282 -0.019
201308 -0.014 98.675 -0.018
201311 -0.014 98.334 -0.018
201402 -0.020 99.057 -0.025
201405 -0.013 100.373 -0.016
201408 -0.014 100.352 -0.018
201411 -0.014 99.635 -0.018
201502 -0.014 99.032 -0.018
201505 -0.015 100.333 -0.019
201508 -0.007 100.548 -0.009
201511 -0.007 100.135 -0.009
201602 -0.007 100.040 -0.009
201605 -0.014 101.355 -0.017
201608 -0.014 101.617 -0.017
201611 -0.007 101.829 -0.009
201702 -0.007 102.779 -0.009
201705 -0.007 103.256 -0.009
201708 -0.013 103.587 -0.016
201711 -0.013 104.072 -0.016
201802 -0.026 105.052 -0.031
201805 -0.020 106.148 -0.024
201808 -0.007 106.383 -0.008
201811 0.000 106.338 0.000
201902 -0.013 106.649 -0.015
201905 -0.013 108.048 -0.015
201908 -0.014 108.245 -0.016
201911 -0.007 108.519 -0.008
202002 -0.014 109.139 -0.016
202005 -0.013 108.175 -0.015
202008 0.019 109.662 0.022
202011 0.006 109.793 0.007
202102 -0.013 110.968 -0.015
202105 -0.007 113.576 -0.008
202108 -0.007 115.421 -0.008
202111 -0.014 117.269 -0.015
202202 -0.007 119.703 -0.007
202205 -0.002 123.323 -0.002
202208 -0.008 124.958 -0.008
202211 -0.007 125.607 -0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bioasis Technologies  (FRA:107) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Bioasis Technologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies Headlines

No Headlines